Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

To join this study, you need to be an adult, 18 years or older, with either Follicular Lymphoma or Large B-Cell Lymphoma that has come back or hasn't responded to at least two previous lines of treatment. Your doctors will also check your general health, including your ability to do daily activities, and make sure your blood, liver, kidney, and heart functions are good enough for you to safely take part.

There are also some reasons why you might not be able to join. For example, if your lymphoma affects your brain or spinal cord, or if you have certain other serious health conditions like a history of previous severe strokes or mental illnesses. You also can't have had certain types of strong cancer treatments or transplants very recently, as these might affect how Surovatamig works or increase risks.

Your study doctor will carefully go through all the detailed requirements with you to see if this study is a good match for your health and medical history. They will ensure it's safe for you to participate.

If you decide to take part in this study, you would receive Surovatamig as an intravenous (IV) infusion, meaning it's given directly into a vein, similar to a drip. You would come to the hospital or clinic for these treatments and for regular check-ups. During these visits, doctors and nurses will do various tests, like blood tests, and scans (PET or CT scans) to see how your body is responding to the medicine and to monitor your general health.

These visits are important for your safety and to understand how well the treatment is working. The study will involve a treatment period, where you receive the medication, followed by a period where your health will continue to be monitored, even after you stop taking the study drug. Your study team will explain the exact schedule of visits, how long each treatment takes, and the total duration of your participation in the study, including follow-up appointments.